Singapore markets closed

Adverum Biotechnologies, Inc. (0HA3.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
10.41+0.75 (+7.80%)
At close: 06:57PM BST
Full screen
Previous close9.66
Open10.44
Bid0.00 x N/A
Ask0.00 x N/A
Day's range10.30 - 10.49
52-week range0.69 - 10.49
Volume395
Avg. volume27,079
Market cap8.357M
Beta (5Y monthly)0.79
PE ratio (TTM)N/A
EPS (TTM)-1.58
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

    REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m. ET.BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.H.C. Wainwright

  • Zacks

    Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

    REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (